Key terms
About INCY
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INCY news
Apr 08
10:40pm ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
Apr 01
8:42am ET
Incyte gets payment from CMS Skinhealth for povorcitinib commercialization
Apr 01
8:37am ET
Incyte, CMS enter collaboration, license agreement for povorcitinib in China
Mar 24
9:48pm ET
RBC Capital Sticks to Its Hold Rating for Incyte (INCY)
Mar 21
10:50am ET
Incyte participates in a conference call with JPMorgan
Mar 21
10:03am ET
Incyte participates in a conference call with JPMorgan
Mar 13
7:40am ET
Analysts Are Bullish on Top Healthcare Stocks: biote (BTMD), Incyte (INCY)
Mar 13
7:16am ET
Incyte price target lowered to $67 from $69 at BofA
Mar 13
6:50am ET
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY)
Mar 13
12:25am ET
Incyte’s Hold Rating: Balancing Clinical Promise Against Financial and Market Position
Mar 12
8:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD)
Mar 12
6:50am ET
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Korro Bio (KRRO) and Incyte (INCY)
Mar 12
6:40am ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), AnaptysBio (ANAB) and iTeos Therapeutics (ITOS)
Mar 12
5:20am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Fortrea Holdings Inc. (FTRE) and Abbott Labs (ABT)
Mar 11
11:55am ET
Incyte to hold a conference call
Mar 11
7:08am ET
Incyte’s Growth Potential Weighed Against Upcoming Challenges: A Hold Rating Analysis
Mar 11
4:55am ET
Incyte to hold a conference call
Mar 10
4:25pm ET
Incyte announces new data from Phase 2 study evaluating ruxolitinib cream
Mar 10
4:22pm ET
Incyte presents late-breaking data from Phase 2 trial evaluating povorcitinib
Mar 05
7:40am ET
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Insmed (INSM)
Feb 27
4:13pm ET
Incyte says FDA grants priority review for axatilimab
Feb 23
9:37am ET
Block upgraded, Rivian downgraded: Wall Street’s top analyst calls
Feb 23
4:43am ET
Incyte initiated with a Buy at Jefferies
Feb 16
8:00am ET
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Gilead Sciences (GILD) and Shockwave Medical (SWAV)
Feb 15
2:55am ET
Incyte Corporation: A Hold Recommendation Amidst Modest Growth and Pipeline Developments
Feb 15
1:20am ET
Analysts Offer Insights on Healthcare Companies: Lantheus (LNTH), Incyte (INCY) and Fusion Pharmaceuticals (FUSN)
Feb 14
9:21am ET
Incyte price target raised to $64 from $58 at BMO Capital
Feb 14
9:12am ET
Incyte price target raised to $65 from $63 at RBC Capital
Feb 14
9:11am ET
Incyte price target raised to $68 from $67 at Stifel
Feb 14
8:55am ET
Incyte price target lowered to $84 from $91 at Truist
Feb 14
7:28am ET
Incyte price target lowered to $88 from $92 at TD Cowen
No recent press releases are available for INCY
INCY Financials
Key terms
Ad Feedback
INCY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INCY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
